1. Implications of the tumor immune microenvironment for staging and therapeutics;Taube,2018
2. LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer;Solinas,2019
3. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor;Ruffo,2019
4. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial;Tawbi,2017
5. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of the SARC028 expansion cohorts;Burgess,2019